Contribution of F-18 Fluoro-Deoxy-Glucose PET/CT (Positron Emission Tomography) to the Assessment of HCC (Hepato-cellular Carcinoma) Treatment Efficiency

NCT ID: NCT01322477

Last Updated: 2011-03-24

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 25 participants
• Study Classification: OBSERVATIONAL

Brief Summary

HCC (Hepato-cellular Carcinoma) is the fifth most frequent cancer in humans and its prevalence is growing. The most effective treatment of HCC is surgical and includes resection and liver transplantation; however, only 20% of the patients can be treated surgically. Local interventional therapy, such as radiofrequency (RF) ablation and transarterial embolization is also used.

Recurrence rate is very high, and extrahepatic disease develops in about 30% of the cases and in up to 20% after liver transplantation.

Systemic treatment is thus an option. Sorafenib (multi-kinase inhibitor) is the first agent to significantly improve the overall survival in advanced HCC. However, the drug has serious side effects and is very expensive.

PET/CT with F18-FDG is a common tool for systemic evaluation and staging of various tumors.

The value of the FDG PET for evaluation of HCC is controversial, in particular due to the unique metabolic pathway of glucose in the HCC cells. Since 2007 more and more studies suggest the feasibility of FDG PET/CT for monitoring local recurrence (especially after RF) and metastatic spread of HCC, including detection of active disease only suspected by AFP (alphafoetoprotein) elevation.

Early detection of treatment response to therapy by whole body FDG PET/CT allows for change of treatment as early as possible,when the tumor is non-responsive before serious side effects appear or before depletion of body resources.

The aim of our study is to investigate the contribution of FDG PET/CT to assessment of treatment response.

Conditions

Hepatocellular Carcinoma

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Hepatocellular Carcinoma

Patients with advanced HCC

F18-FDG PET/CT

Intervention Type: OTHER

Interventions

F18-FDG PET/CT

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• advanced HCC for systemic treatment

Exclusion Criteria

• HCC only localized in liver,
• Other liver disease (e.g. metastases and benign lesions)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hadassah Medical Organization

OTHER

Sponsor Role: lead

Locations

Hadassah Hebrew University Medical Center

Jerusalem, , Israel

Countries

Israel

Central Contacts

Marina Orevi, MD

Role: CONTACT

marinaor@hadassah.org.il

97250-8946211

Roland Chisin, MD

Role: CONTACT

CHISIN@hadassah.org.il

9726776705

Facility Contacts

Marina Orevi, MD

Role: primary

marinaor@hadassah.org.il

0508946211

Roland Chisin, MD

Role: backup

chisin@hadassah.org.il

Other Identifiers

0022-11-HMO

Identifier Type: -

Identifier Source: org_study_id